Samsung's presence in the South Korean smartphone market would further expand with LG Electronics' withdrawal from the mobile business, industry observers said.
Samsung is already the market leader and LG's departure would limit alternatives for local consumers.
LG Electronics Inc. will become the first major smartphone brand to pull out from the mobile business after years of money-losing performance after failing to find a buyer.
The company was in talks with Vingroup of Vietnam and Volkswagen of Germany to sell the mobile business. Negotiations fell through.
Once the world's third-largest handset maker, LG was relegated to ninth spot last year after shipping 24.7 million smartphones with a market share of 2 percent, down 13 percent from a year earlier.
The South Korean firm's mobile communications (MC) unit will stop producing and selling handsets after July 31 due to its long slump and fierce competition.
It also scrapped its plan to launch a smartphone with a rollable OLED display.
LG will produce handsets until end-May to meet existing orders and would provide sufficient after-sales services.
The decision ends LG's mobile business that first started in 1995.


OpenAI Tightens AI Safety Monitoring After Security Incidents
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme
REPAY Stock Rises After Visa Platform Connect Collaboration
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
Google to Move All Pixel Production Out of China by 2027
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth
Coty Revenue Beats Estimates as Beauty Demand Holds Firm
Shein Targets $26B-$27B Valuation for Hong Kong IPO
Ferrari Luce EV Sells for Record $40 Million at Charity Auction
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 



